Indeed, our findings of non-hypoxic stabilization of HIF-1α suggest that it might be possible to develop a small molecule interfering with the ERβ2 and ERβ5-induced HIF-1α stabilization for use in therapy of certain aggressive forms of prostate cancer. This evidence concerns the gene HIF1A and prostate cancer.